Radium-223 therapy for bone metastasis from prostate cancer

Contract summary

Industry

• Health and social work services - 85000000

Location of contract

East Midlands

Value of contract

£88,000 to £1,500,000

Procurement reference

NGH001-DN220405-82099297/2

Published date

22 December 2016

Closing date

3 December 2016

Contract start date

5 December 2016

Contract end date

21 December 2020

Contract type

Supply contract

Procedure type

Other:

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

---

Description

NGHT has had to publish a VEAT notice for the following therapy:
Xofigo (Radium 223) Dose.

The reason for the VEAT notice was due to:
"There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years.
This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial). Currently these patients are either sent elsewhere for the same treatment, or they do not receive treatment.
This is the only radiopharmaceutical that has been granted NICE approval for treatment of bone metastasis, and is the only Radium (223) product currently available commercially.

---

More information

Previous notice about this procurement

Radium-223 therapy for bone metastasis from prostate cancer

• Opportunity
• Published 28 November 2016

---

Award information

Awarded date

24 November 2016

Contract start date

22 December 2016

Contract end date

3 September 2020

Total value of contract

£2,200,000

This contract was awarded to 1 supplier.

Bayer PLC

---

About the buyer

Contact name

Paul Scotland

Address

Northampton General Hospital
Cliftonville
Northampton
NN1 5BD
England

Telephone

+44 1604544401

Email

paul.scotland@ngh.nhs.uk

Website

http://www.northamptongeneral.nhs.uk/Home.aspx